Harrow (HROW) Cash & Current Investments (2010 - 2026)
Harrow (HROW) recorded quarterly Cash & Current Investments of $94.6 million in Q1 2026, up 29.78% quarter-over-quarter from $72.9 million in Q4 2025, and up 41.84% on a YoY basis from $66.7 million in Q1 2025.
Harrow (HROW) Cash & Current Investments (2010 - 2026) Analysis & Trends
Harrow's Cash & Current Investments history runs 17 years deep, the most recent figure standing at $94.6 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 41.84% year-over-year to $94.6 million; the TTM figure through Mar 2026 stood at $94.6 million (up 41.84% YoY), while the FY2025 annual figure was $72.9 million, up 54.35% from the prior year.
- Cash & Current Investments was $94.6 million for Q1 2026 at Harrow, up from $72.9 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $101.9 million in Q4 2022 to a low of $26.9 million in Q1 2023.
- Historically, Cash & Current Investments has averaged $64.4 million across 5 years, with a median of $71.0 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Cash & Current Investments jumped 677.83% in 2022, then slumped 46.87% in 2023.
- A 5-year view of Cash & Current Investments shows it stood at $101.9 million in 2022, then decreased by 18.74% to $82.8 million in 2023, then sank by 42.91% to $47.2 million in 2024, then surged by 54.35% to $72.9 million in 2025, then gained by 29.78% to $94.6 million in 2026.
- The last three Cash & Current Investments figures came in at $94.6 million (Q1 2026), $72.9 million (Q4 2025), and $74.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 3.74 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.94 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 2.15 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 77.77 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.32 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 428.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 511.86 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 750.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 498.58 Mn |
| 10 | Harrow | 1.25 Bn | 1.15 Bn | 27.05 Mn | 94.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.64 Mn |
| Dec 31, 2025 | 72.93 Mn |
| Sep 30, 2025 | 74.29 Mn |
| Jun 30, 2025 | 52.96 Mn |
| Mar 31, 2025 | 66.73 Mn |
| Dec 31, 2024 | 47.25 Mn |
| Sep 30, 2024 | 72.60 Mn |
| Jun 30, 2024 | 70.97 Mn |
| Mar 31, 2024 | 75.97 Mn |
| Dec 31, 2023 | 82.77 Mn |
| Sep 30, 2023 | 73.88 Mn |
| Jun 30, 2023 | 29.67 Mn |
| Mar 31, 2023 | 26.88 Mn |
| Dec 31, 2022 | 101.86 Mn |
| Sep 30, 2022 | 49.12 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | 50.59 Mn |
| Dec 31, 2021 | 50.67 Mn |
| Sep 30, 2021 | 67.85 Mn |
| Jun 30, 2021 | 85.06 Mn |